Form 8-K - Current report:
SEC Accession No. 0001140361-21-036477
Filing Date
2021-11-04
Accepted
2021-11-03 21:49:04
Documents
14
Period of Report
2021-11-03
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K brhc10030396_8k.htm   iXBRL 8-K 24190
2 EXHIBIT 99.1 brhc10030396_ex99-1.htm EX-99.1 108216
6 image00001.jpg GRAPHIC 5423
  Complete submission text file 0001140361-21-036477.txt   286958

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rckt-20211103.xsd EX-101.SCH 3935
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rckt-20211103_lab.xml EX-101.LAB 22544
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rckt-20211103_pre.xml EX-101.PRE 16050
7 EXTRACTED XBRL INSTANCE DOCUMENT brhc10030396_8k_htm.xml XML 4057
Mailing Address 350 FIFTH AVENUE SUITE 7530 NEW YORK NY 10118
Business Address 350 FIFTH AVENUE SUITE 7530 NEW YORK NY 10118 646-440-9100
ROCKET PHARMACEUTICALS, INC. (Filer) CIK: 0001281895 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36829 | Film No.: 211377714
SIC: 2834 Pharmaceutical Preparations